ASARINA PHARMA

Remain in control of your life

Annual General Meeting
5 May 2020
Peter Nordkild, CEO

Disclaimer

- The shares of Asarina Pharma (”Asarina”) are traded on NASDAQ First North in Stockholm (ticker: ”ASAP”)
- This presentation may contain specific forward-looking statements, relating to Asarina´s future business, development and economic performance e.g. statements including terms like ”believe”, ”assume”, ”expert” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Asarina and those explicitly or implicitly presumed in these statements
- Against the background of these uncertainties readers should not rely on forward-looking statements
- Asarina assumes no responsibility to update forward-looking statements or to adapt them to future events or developments

Introduction

- Due to the Covid-19 restrictions, Asarina management is unable to physically attend the 2019 Annual General Meeting

- The CEO and the CFO will participate by video and will be available to answer questions

- The following slides include the presentation by Peter Nordkild of the current situation in Asarina.

Asarina – highlights May 2020

- **PMDD**: No statistical difference in clinical endpoints between placebo and Sepranolone in phase IIb study
  - Strong safety profile for Sepranolone confirmed
  - Additional data analysis – unlikely to change overall result
- **Menstrual migraine**: 75% of patients recruited in phase IIa study - topline results expected in first half of 2021
- **Tourette Syndrome**: phase IIa study to be initiated in Q2 2021 - topline results in Q1 2022
- Both phase IIa studies are fully funded

CONFIDENTIAL

PMDD - phase IIb results

Phase IIb Clinical Study Design

A randomised, double-blind, placebo-controlled, parallel-group, multicentre study investigating the efficacy and safety of Sepranolone (UC1010) in patients with PMDD

2 cycles baseline / diagnosis | 3 cycles treatment | 1 cycle follow-up





Phase IIb Clinical Study
Treatment effect

- Late luteal phase symptom scores in the ITT population (N=192)



Phase IIb Clinical Study
Treatment effect

- Improvement in late luteal phase symptom scores from baseline in the ITT population (N=192)

	Sepranolone 10 mg	Sepranolone 16 mg	Placebo	**Difference Active-Placebo**	**Active vs. Placebo**
Total symptoms (Sum21)	30.5±22.2	30.0±20.2	27.9±21.4	2.4±21	NS (p=0.3)
Cardinal symptoms	13.7±10.0	13.4±9.7	12.4±10.0	1.1±9.8	NS (p=0.3)
Impairment score	5.1±3.7	5.3±3.6	4.5±3.8	0.7±3.7	NS (p=0.2)

Average ± SD

- Total symptom (Lmax Sum21) expressed as frequency % improvement

	>50%	**>75%**
Active	52	25
Placebo	45	15

Phase IIb Clinical Study
Treatment effect

- Improvement in late luteal phase symptom scores in the ITT population (N=192)



Phase IIb Clinical Study
Adverse events

- No treatment related Serious Adverse Events has been reported

- In total 236 probably/possibly related Adverse Events were reported
  - The vast majority were mild and transient, none was severe
  - No single type of general adverse event occurred in more than 3% of the patients and no relation to treatment group

More specifically

- The events related to the Sepranolone injection sites occurred in 20 % of the patients
- The vast majority of these were mild and transient, none was severe

Menstrual Migraine - phase IIa study

Menstrual Migraine: Phase IIa (APH204)

- 7 study sites: 3 in Finland, 4 in Sweden
- 86 women to be randomized
- Study includes a baseline/diagnostic phase of 3 menstrual cycles, followed by 3 cycles of sepranolone/placebo
- Daily eDiary ratings
- Due to COVID-19 related recruitment restrictions, estimated LPLV Q1 2021





CONFIDENTIAL

APH204 Population status



Subjects enrolled: 86

Screen failures: 21

Randomized: 33

Started T1:

Withdrawn: 1

Started T2:

Withdrawn: 0

Started T3:

Withdrawn: 0

Completers: 18

- Approx. 20% screen failure rate
- Compliance: 80% of days need to be completed in eDiary
- Once started treatment cycles – 1 withdrawal so far
- Recruitment by FB, ads, emails in patient organizations, doctors' own databases

CONFIDENTIAL

Tourette - phase IIa study

Efficacy on par with Haldol and Finasteride

Spatial confinement





Source of Variation	% of total variation	P value	P value summary	Significant?	
Interaction	16.23	<0.0001	****	Yes	
Row Factor	23.85	<0.0001	****	Yes	
Column Factor	33.18	<0.0001	****	Yes	
ANOVA table	SS (Type III)	DF	MS	F (DFn, DFd)	P value
Interaction	0.4598	3	0.1533	F (3, 48) = 9.716	P<0.0001
Row Factor	0.6754	1	0.6754	F (1, 48) = 42.82	P<0.0001
Column Factor	0.9398	3	0.3133	F (3, 48) = 19.86	P<0.0001

All movements were scored by personnel blinded to treatment and genotype; n=7/group

Analysis: 2-way ANOVA followed by Tukey's post-hoc tests

Phase IIa study in Tourette



- A randomized parallel group Phase IIa study in drug naive adolescent and adult patients with TS
- ~30 male and female TS patients, age 12-45, randomized 2:1 to sepranolone and non-drug treatment or non-drug treatment alone
- 1-month baseline period, patients will receive Sepranolone every other day for 3 months*
- Primary endpoint: reduction of tics on the YGTSS** scale
  Cut off > 25% tic redution

* Due to natural waxing and waning of tics, too short observation periods tend to overestimate effects

**Yale Global Tic Severity Scale (YGTSS) (McGuire et al 2018)

CONFIDENTIAL

Near term value inflection points



✓ IND approved for Menstrual Migraine July 2019

CONFIDENTIAL

THANK YOU

QUESTIONS?